Anixa Biosciences Awarded New U.S. Patent Extending Breast Cancer Vaccine IP Protection into 2040s

By Editorial Team

Anixa Biosciences, a biotechnology company specializing in cancer treatment and prevention, has been granted a new U.S. patent that extends the intellectual property protection of its breast cancer vaccine technology into the 2040s. The patent, numbered 12,370,244, focuses on immunizing patients against breast cancer by utilizing a composition containing human α-lactalbumin protein, which is present in breast tissue during lactation and certain breast cancers. This innovative approach aims to address the significant unmet need in preventive oncology, particularly in the realm of breast cancer.

The breast cancer vaccine developed by Anixa Biosciences in collaboration with Cleveland Clinic offers a unique strategy for preventing and treating breast cancer. The vaccine targets the α-lactalbumin protein, which is expressed in specific breast cancers, with the goal of stimulating the immune system to identify and eliminate pre-malignant and malignant cells while preserving normal tissue. This vaccine platform has the potential to provide long-lasting immune protection with minimal off-target effects.

With breast cancer being one of the most commonly diagnosed cancers among women globally, the absence of an FDA-approved vaccine for prevention underscores the urgency for innovative solutions in the field. Anixa's vaccine program not only addresses this critical need but also presents a significant market opportunity, especially for women at high risk of developing aggressive forms of breast cancer like triple-negative breast cancer (TNBC).

Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences, emphasized the importance of the company's breast cancer vaccine program in revolutionizing preventive immunotherapies. The newly issued patent further solidifies Anixa's position as a leader in this sector, with a strong portfolio of patents supporting the development and commercialization of advanced immunopreventive solutions.

Anixa Biosciences is also actively engaged in other cancer treatment initiatives, including an ovarian cancer immunotherapy program developed in partnership with Moffitt Cancer Center. By collaborating with renowned research institutions, Anixa continues to explore emerging technologies in cancer immunotherapy to address various forms of cancer.

For more information about Anixa Biosciences and its innovative cancer treatment and prevention programs, visit www.anixa.com.